Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

Identification of novel functional inhibitors of 17beta-hydroxysteroid dehydrogenase type III (17beta-HSD3).

Spires TE, Fink BE, Kick EK, You D, Rizzo CA, Takenaka I, Lawrence RM, Ruan Z, Salvati ME, Vite GD, Weinmann R, Attar RM, Gottardis MM, Lorenzi MV.

Prostate. 2005 Oct 1;65(2):159-70.

PMID:
15924334
2.

Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.

Day JM, Tutill HJ, Foster PA, Bailey HV, Heaton WB, Sharland CM, Vicker N, Potter BV, Purohit A, Reed MJ.

Mol Cell Endocrinol. 2009 Mar 25;301(1-2):251-8. doi: 10.1016/j.mce.2008.08.014. Epub 2008 Aug 22.

PMID:
18786604
3.

The design of novel 17beta-hydroxysteroid dehydrogenase type 3 inhibitors.

Vicker N, Sharland CM, Heaton WB, Gonzalez AM, Bailey HV, Smith A, Springall JS, Day JM, Tutill HJ, Reed MJ, Purohit A, Potter BV.

Mol Cell Endocrinol. 2009 Mar 25;301(1-2):259-65. doi: 10.1016/j.mce.2008.08.005. Epub 2008 Aug 15.

PMID:
18775469
4.

The UV-filter benzophenone-1 inhibits 17beta-hydroxysteroid dehydrogenase type 3: Virtual screening as a strategy to identify potential endocrine disrupting chemicals.

Nashev LG, Schuster D, Laggner C, Sodha S, Langer T, Wolber G, Odermatt A.

Biochem Pharmacol. 2010 Apr 15;79(8):1189-99. doi: 10.1016/j.bcp.2009.12.005. Epub 2009 Dec 11.

PMID:
20005209
5.

Identification of a novel series of tetrahydrodibenzazocines as inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.

Fink BE, Gavai AV, Tokarski JS, Goyal B, Misra R, Xiao HY, Kimball SD, Han WC, Norris D, Spires TE, You D, Gottardis MM, Lorenzi MV, Vite GD.

Bioorg Med Chem Lett. 2006 Mar 15;16(6):1532-6. Epub 2006 Jan 4.

PMID:
16386902
6.

STX2171, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model.

Day JM, Foster PA, Tutill HJ, Schmidlin F, Sharland CM, Hargrave JD, Vicker N, Potter BV, Reed MJ, Purohit A.

Endocr Relat Cancer. 2013 Feb 18;20(1):53-64. doi: 10.1530/ERC-12-0231. Print 2013 Feb.

8.
9.

Curcumin derivatives inhibit testicular 17beta-hydroxysteroid dehydrogenase 3.

Hu GX, Liang G, Chu Y, Li X, Lian QQ, Lin H, He Y, Huang Y, Hardy DO, Ge RS.

Bioorg Med Chem Lett. 2010 Apr 15;20(8):2549-51. doi: 10.1016/j.bmcl.2010.02.089. Epub 2010 Mar 1.

PMID:
20346654
10.

In vitro and in vivo evaluation of a 3β-androsterone derivative as inhibitor of 17β-hydroxysteroid dehydrogenase type 3.

Roy J, Fournier MA, Maltais R, Kenmogne LC, Poirier D.

J Steroid Biochem Mol Biol. 2014 May;141:44-51. doi: 10.1016/j.jsbmb.2013.12.019. Epub 2014 Jan 13.

PMID:
24434282
11.

Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-hydroxyphenyl ketones as potent and specific inhibitors of the type 3 of 17beta-hydroxysteroid dehydrogenase (17beta-HSD3).

Lota RK, Olusanjo MS, Dhanani S, Owen CP, Ahmed S.

J Steroid Biochem Mol Biol. 2008 Jul;111(1-2):128-37. doi: 10.1016/j.jsbmb.2008.05.008. Epub 2008 Jun 21.

PMID:
18620056
12.

Development of 17β-hydroxysteroid dehydrogenase type 3 as a target in hormone-dependent prostate cancer therapy.

Ning X, Yang Y, Deng H, Zhang Q, Huang Y, Su Z, Fu Y, Xiang Q, Zhang S.

Steroids. 2017 May;121:10-16. doi: 10.1016/j.steroids.2017.02.003. Epub 2017 Mar 4. Review.

PMID:
28267564
13.

Inhibition of human and rat 3beta-hydroxysteroid dehydrogenase and 17beta-hydroxysteroid dehydrogenase 3 activities by perfluoroalkylated substances.

Zhao B, Hu GX, Chu Y, Jin X, Gong S, Akingbemi BT, Zhang Z, Zirkin BR, Ge RS.

Chem Biol Interact. 2010 Oct 6;188(1):38-43. doi: 10.1016/j.cbi.2010.07.001. Epub 2010 Jul 7.

PMID:
20619251
14.

Effects of methoxychlor and 2,2-bis(p-hydroxyphenyl)-1,1,1-trichloroethane on 3β-hydroxysteroid dehydrogenase and 17β-hydroxysteroid dehydrogenase-3 activities in human and rat testes.

Hu GX, Zhao B, Chu Y, Li XH, Akingbemi BT, Zheng ZQ, Ge RS.

Int J Androl. 2011 Apr;34(2):138-44. doi: 10.1111/j.1365-2605.2010.01065.x.

PMID:
20522127
15.

Phytoestrogens inhibit human 17beta-hydroxysteroid dehydrogenase type 5.

Krazeisen A, Breitling R, Möller G, Adamski J.

Mol Cell Endocrinol. 2001 Jan 22;171(1-2):151-62.

PMID:
11165023
17.

Coumarins as novel 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for potential treatment of prostate cancer.

Harada K, Kubo H, Tomigahara Y, Nishioka K, Takahashi J, Momose M, Inoue S, Kojima A.

Bioorg Med Chem Lett. 2010 Jan 1;20(1):272-5. doi: 10.1016/j.bmcl.2009.10.111. Epub 2009 Nov 10.

PMID:
19954971
18.

Development of 3-substituted-androsterone derivatives as potent inhibitors of 17β-hydroxysteroid dehydrogenase type 3.

Maltais R, Fournier MA, Poirier D.

Bioorg Med Chem. 2011 Aug 1;19(15):4652-68. doi: 10.1016/j.bmc.2011.06.003. Epub 2011 Jun 13.

PMID:
21741247
19.

Design, chemical synthesis and biological evaluation of 3-spiromorpholinone/3-spirocarbamate androsterone derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase type 3.

Djigoué GB, Kenmogne LC, Roy J, Maltais R, Poirier D.

Bioorg Med Chem. 2015 Sep 1;23(17):5433-51. doi: 10.1016/j.bmc.2015.07.049. Epub 2015 Jul 29.

PMID:
26277760
20.

Effects of phthalates on 3β-hydroxysteroid dehydrogenase and 17β-hydroxysteroid dehydrogenase 3 activities in human and rat testes.

Yuan K, Zhao B, Li XW, Hu GX, Su Y, Chu Y, Akingbemi BT, Lian QQ, Ge RS.

Chem Biol Interact. 2012 Feb 5;195(3):180-8. doi: 10.1016/j.cbi.2011.12.008. Epub 2011 Dec 27.

PMID:
22214983

Supplemental Content

Support Center